TTD | Drug: D00HPD

Drug General Information
Drug ID	D00HPD
Former ID	DNCL003374
Drug Name	Moxetumomab pasudotox
Synonyms	CAT-8015; GCR-8015; HA22
Drug Type	Monoclonal antibody
Indication	Haematological malignancies [ICD9: 200-209; ICD10:C81-C86]		Phase 1	[551581]
Therapeutic Class	Anticancer Agents
Company	AstraZeneca
Target and Pathway
Target(s)	B-cell receptor CD22	Target Info	Modulator	[531663]
KEGG Pathway	Cell adhesion molecules (CAMs)
	Hematopoietic cell lineage
	B cell receptor signaling pathway
PANTHER Pathway	B cell activation
Pathway Interaction Database	BCR signaling pathway
Reactome	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Reactome	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
WikiPathways	B Cell Receptor Signaling Pathway
References
Ref 551581	Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies
Ref 531663	Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.

Drug Information